Why the study?
What sociodemographic, medical, and psychosocial factors are associated with prediabetes and type 2 diabetes in patients after myocardial infarction or coronary revascularization?
What sociodemographic, medical, and psychosocial factors are associated with prediabetes and type 2 diabetes in patients after myocardial infarction or coronary revascularization?
In patients with recent coronary events, prediabetes is associated with smoking and non-participation in cardiac rehabilitation, while type 2 diabetes is associated with obesity, hypertension, insomnia, and low drug adherence, highlighting the need for tailored secondary prevention.
Answers are grounded in this paper and cite their sources.
Supports targeted prediabetes screening in post-MI smokers and rehab nonparticipants; leaves open causal effects and intervention benefits.
BACKGROUND: Understanding the determinants associated with prediabetes and type 2 diabetes in coronary patients may help to individualize treatment and modelling interventions. We sought to identify sociodemographic, medical and psychosocial factors associated with normal blood glucose (HbA1c < 5.7%), prediabetes (HbA1c 5.7-6.4%), and type 2 diabetes. METHODS: level) in 1083 patients with myocardial infarction and/or a coronary revascularization procedure. Data were collected from hospital records at the index event and from a self-report questionnaire and clinical examination with blood samples at 2-36 months follow-up. RESULTS: was associated with larger waist circumference (β 0.13, p < 0.001), smoking (β 0.18, p < 0.001), hypertension (β 0.08, p = 0.04), older age (β 0.16, p < 0.001), and non-participation in cardiac rehabilitation (β 0.11, p = 0.005). CONCLUSIONS: Along with obesity and hypertension, insomnia and low drug adherence were the major modifiable factors associated with type 2 diabetes, whereas smoking and non-participation in cardiac rehabilitation were the factors associated with prediabetes. Further research on the effect of individual tailoring, addressing the reported significant predictors of failure, is needed to improve glycaemic control. TRIAL REGISTRATION: Retrospectively registered at ClinicalTrials.gov: NCT02309255 , December 5th 2014.
No takes yet. Share an insight, caveat, or question.
Munkhaugen et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: